Pinnacle Medicines Raises $89M for Oral Peptides Matching Injectable Biologics
OrbiMed-incubated startup revealed $89M in funding to develop oral peptide drugs with biologic-level efficacy. Lead program targets asthma and is on track for clinical trials.